Analysis
As of November 22, 2026, IQVIA Holdings is closing in on a takeover of UK drug development services group Quotient Sciences for about $1.1 billion, Bloomberg reported, citing people familiar with the talks. The seller is buyout firm Permira, which has owned Quotient since 2019, and a deal could be unveiled as soon as Monday, barring any late surprises, per Briefs. Spokespeople for IQVIA and Permira declined to comment, and nothing has been signed.
For a $40 billion company the check is small. The reason it leads today is what it says about the exit market: a strategic buyer is paying up for a private-equity-held asset, and Permira is on a run of exactly that kind of sale.
What does Quotient Sciences do?
Quotient Sciences is a contract research and manufacturing company based in Nottingham, England. Its own site describes it as "providing contract research and contract manufacturing expertise across all stages" of drug development, and says its customers range "from small biotechs up to Fortune 100-ranked global pharmaceutical companies" (Quotient Sciences). The same page says "Since 1990, Quotient Sciences has transformed into a trusted global drug development partner."
“The same page says "Since 1990, Quotient Sciences has transformed into a trusted global drug development partner." Its pitch is speed in early clinical work.”
Its pitch is speed in early clinical work. Quotient markets a model it calls Translational Pharmaceutics, which it describes as "seamlessly integrating formulation development, drug product manufacturing and clinical testing" under one roof. In practice that means a biotech can formulate a compound, make trial supplies and run the study that shows how the drug behaves in the body without handing the molecule between three vendors. Briefs describes the business the same way: early-stage drug development and clinical manufacturing for pharma and biotech clients.
Quotient Sciences ownership history
Quotient has changed private-equity hands before. The ownership rows we could verify:
- Jul 2019, majority buyout -- Permira Funds agreed to buy a majority stake from companies controlled by GHO Capital and other investors "for an undisclosed sum" (Permira). Bloomberg reported at the time that the deal valued Quotient at about 600 million pounds, or $745 million, including debt (Private Equity International).
- Nov 2026, reported sale -- IQVIA nearing a deal at about $1.1 billion (Briefs).
Value Add VC data
- Jul 2019, Permira majority buyout -- undisclosed officially; about $745M including debt as reported by Bloomberg, sold by GHO Capital (Permira)
- Nov 2026, IQVIA takeover (reported, not signed) -- about $1.1B (Briefs)
On those two reported figures the new price is roughly 1.5 times the 2019 mark. That comparison is loose: the 2019 number included debt, the 2026 report does not say whether $1.1 billion is equity or enterprise value, and seven years of a currency move sit between them. Three comparable sales by the same seller or the same buyer:
- Octus to London Stock Exchange Group -- about $3.5 billion, a Permira exit, per Briefs; Pulse covered the LSEG-Octus deal when it was announced.
- BioCatch to Visa -- $2.4 billion, another Permira sale to a strategic buyer, per Briefs.
- Charles River discovery assets to IQVIA -- five in vitro discovery sites, announced February 25, 2026 with no price in IQVIA's release, and completed in May, per Briefs.
Who is selling, and why IQVIA is buying
If the deal completes, Permira's sale of Quotient would be its eighth transaction with a strategic buyer this year, Briefs reported. Pulse tracks the firm's other recent exits on its Permira hub. That count is the part founders and GPs should read closely. Sponsor-to-sponsor deals and IPOs were the default exit routes of the last cycle; a buyout firm clearing eight assets to corporates in one year means strategic acquirers are the ones writing checks at prices sellers accept.
IQVIA is a clinical research group headquartered in Durham, North Carolina. Its shares closed Friday in New York at $245.82, up about 9% this year, for a market value near $40.5 billion, per Briefs. At about $1.1 billion, Quotient would cost under 3% of that value. Strategically it stacks: the Charles River assets gave IQVIA discovery-stage labs, its core business is running trials, and Quotient sits between the two at formulation and clinical-supply manufacturing.
What could still go wrong
The deal is reported, not announced. Bloomberg's sources hedge on timing ("barring any late surprises"), and neither company has confirmed a price. A UK target also means a UK regulatory review is possible. And a contract manufacturer is only as good as its utilisation: early-stage biotech spending is the first budget cut when funding tightens, so the multiple IQVIA pays depends on a pipeline of small clients it does not control. The earliest confirmation point is Monday, November 23.